Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 5/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14693112 | 0.87 | DRD2 (0.49) | DRD2HTR1AHTR2AEPHX1MAPT | |
| SCHEMBL3211335 | 0.86 | DRD2 (0.48) | DRD2HTR1AHTR2AEPHX1CNR1 | |
| SCHEMBL3222663 | 0.84 | DRD2 (0.47) | DRD2HTR1AHTR2AEPHX1CNR1 | |
| SCHEMBL3205743 | 0.82 | KMT2A (0.46) | CNR1CNR2RAB9A | |
| SCHEMBL13343040 | 0.78 | SMAD3 (0.54) | DRD2HTR1AHTR2AMAPTALDH1A1 | |
| SCHEMBL937815 | 0.74 | KMT2A (0.43) | DRD2HTR1AHTR2ACNR1CNR2 | |
| SCHEMBL183887 | 0.74 | PRKDC (0.42) | DRD2HTR1AHTR2AALDH1A1PDE10A | |
| SCHEMBL183886 | 0.74 | PRKDC (0.42) | DRD2HTR1AHTR2AALDH1A1PDE10A | |
| SCHEMBL1084995 | 0.73 | HIF1A (0.45) | DRD2HTR1AHTR2ACNR1CNR2 | |
| SCHEMBL13157350 | 0.72 | DRD2 (0.41) | DRD2HTR1AHTR2ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372843-B2 | Quinolines useful as modulators of ION channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372843-B2 | Quinolines useful as modulators of ION channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372843-B2 | Quinolines useful as modulators of ION channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-7683066-B2 | Isoquinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683066-B2 | Isoquinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683066-B2 | Isoquinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| EP-1891039-A1 | QUINOLINE DERIVATIVES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-03 | — | — | US | disclosed |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-03 | — | — | US | disclosed |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-03 | — | — | US | disclosed |
| WO-2006127329-A1 | QUINOLINE DERIVATIVES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006127329-A1 | QUINOLINE DERIVATIVES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | KCNQ1, KCNQ2, KCNQ5 | DRD2 1304/4885HTR1A 678/4885HTR2A 538/4885 |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNQ5 | DRD2 1304/4885HTR1A 678/4885HTR2A 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.